SWTX241115P45000
- 0.00
- 0.000.00%
SpringWorks Therapeutics Newsroom
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib
Optimistic Future for Springworks Therapeutics Amid Packaging Transition and Market Expansion
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript Summary
SpringWorks Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify Buy Rating
Express News | SpringWorks Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $74 From $76
SpringWorks Therapeutics | 10-Q: Q3 2024 Earnings Report
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
Springworks Therapeutics' Q3 Net Loss Narrows
Express News | SpringWorks Therapeutics Shares Fall 9% Premarket After Q3 Results
SpringWorks Therapeutics' Mirdametinib Shows Efficacy in Neurofibromatosis Study
SpringWorks Therapeutics Q3 2024 GAAP EPS $(0.72) Beats $(0.75) Estimate, Sales $49.30M Miss $53.17M Estimate
Express News | SpringWorks Therapeutics : Cash Expected to Fund Co Through Profitability, Anticipated in H1 2026
Express News | SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | SpringWorks Therapeutics Q3 Operating Income USD -57.937 Million
SpringWorks Therapeutics 3Q Loss/Shr 72c >SWTX
SpringWorks Therapeutics 3Q Loss $53.5M >SWTX